Bozhou Pharmaceutical Industrial Zone Expansion Approved: What This Means for Investors
On March 12, 2025, the Anhui Provincial Government approved a major expansion of the Bozhou Pharmaceutical Industrial Zone, adding 15.8 square kilometers of land dedicated to traditional Chinese medicine (TCM) processing, biotech manufacturing, and logistics. This move cements Bozhou’s position as China’s largest TCM trading hub, which already handles over 30% of the nation’s bulk Chinese medicinal materials.
Expansion Details and Rationale
The new zone, named the Bozhou High-Tech Pharmaceutical Industrial Park Phase III (亳州高新技术制药产业园三期, Bózhōu Gāoxīn Jìshù Zhìyào Chǎnyèyuán), will be developed in two phases over 2025–2028. It will include dedicated areas for GMP-compliant processing, R&D labs, cold-chain storage, and an integrated customs clearance center for exports. The total planned investment is RMB 42.6 billion, with RMB 12 billion coming from local government infrastructure bonds and the remainder from private sources.
Bozhou currently hosts over 200 pharmaceutical and TCM companies, including firms like Anhui Huqingyutang and Bozhou Yinfeng Pharmaceutical. The expansion aims to attract at least 80 new enterprises within three years, focusing on extraction, formulation, and digital supply chain management.
Impact on Investment Climate
This expansion comes at a time when China’s TCM industry is projected to exceed RMB 3 trillion in total output value by 2027, according to the National Administration of Traditional Chinese Medicine. Bozhou alone contributes over RMB 150 billion annually in TCM-related output. The new zone offers foreign investors incentives including three-year corporate income tax reductions, streamlined land-use approvals, and expedited environmental permits for GMP-certified facilities.
Foreign companies considering setting up a 外商独资企业 (Wholly Foreign-Owned Enterprise, WFOE, wàishāng dúzī qǐyè) in the TCM sector should note that Bozhou now provides a “green lane” for registration—cutting typical processing time from 60 days to under 25 days. Furthermore, the zone includes a dedicated GSP-certified (Good Supply Practice, gòuxiāo guīfàn) warehouse complex with 120,000 square meters of space, addressing logistics bottlenecks that previously plagued exporters.
| Parameter | Phase III (New) | Existing Zone (Phase I & II) | % Change |
|---|---|---|---|
| Total area (sq km) | 15.8 | 28.6 | +55.2% |
| Planned investment (RMB) | 42.6 billion | 18.3 billion | +133% |
| Target new enterprises | 80 | N/A (initial buildout) | N/A |
| Projected annual output by 2030 (RMB) | 200 billion | 150 billion (2024) | +33% |
| Employment creation (direct) | 12,000 | 6,800 | +76% |
Strategic Implications for Foreign Investors
For foreign pharmaceutical companies, Bozhou’s expansion offers a rare opportunity to integrate into China’s TCM ecosystem at scale. The zone is designed to support both inbound raw material processing and outbound finished product exports to Southeast Asia, Europe, and Africa.
If you aim to establish a manufacturing base for TCM granules or patented extracts, Bozhou’s park provides pre-approved GMP workshop designs and shared quality-control labs—reducing capital expenditure by an estimated 25–35%. If your focus is on R&D collaboration, the zone has signed agreements with the Chinese Academy of TCM and Anhui University of Chinese Medicine to co-locate research centers.
Pragmatically, the expansion includes a dedicated Bonded Logistics Center (B型保税物流中心) that allows duty-free storage of imported equipment for up to two years—a significant cost saver for companies importing European or Japanese filling line machinery.
How to Evaluate the Investment
If your company’s primary need is expedited market entry, choose a 外商独资企业 (WFOE) structure with a registered capital between RMB 10–30 million to qualify for the zone’s fast‑track registration. If your strategy hinges on partnering with local TCM distributors, a 合资企业 (joint venture, hézī qǐyè) with a Bozhou state‑owned enterprise may offer better access to supply chains.
For companies focused on export to ASEAN markets, the zone’s new customs clearance center reduces inspection time from three days to eight hours, directly improving logistics competitiveness.
NEXT STEPS:
- Read our detailed Guide to Setting Up a WFOE in Anhui – covers capital requirements, timelines, and zone‑specific benefits.
- Access the latest Bozhou Pharmaceutical Zone Incentives Checklist – including tax holidays and subsidy application templates.
- Contact our Anhui Gateway team for a Free Zone‑Match Assessment – we match your product line to the best plot within the expanded area.
— Anhui Gateway —
Remote China market entry support, built around execution.